Wave Life Sciences Ltd (NASDAQ:WVE) – Investment analysts at Leerink Swann issued their Q1 2019 EPS estimates for Wave Life Sciences in a report issued on Monday, March 12th, Zacks Investment Research reports. Leerink Swann analyst G. Porges anticipates that the company will post earnings of ($0.62) per share for the quarter. Leerink Swann has a “Outperform” rating and a $62.00 price target on the stock. Leerink Swann also issued estimates for Wave Life Sciences’ Q2 2019 earnings at ($0.65) EPS, Q3 2019 earnings at ($0.68) EPS and Q4 2019 earnings at ($0.72) EPS.
Several other analysts have also recently weighed in on the stock. Mizuho lifted their price objective on shares of Wave Life Sciences from $34.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, March 19th. SunTrust Banks lifted their price objective on shares of Wave Life Sciences to $60.00 and gave the stock a “buy” rating in a research note on Friday, March 9th. BidaskClub cut shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 3rd. Zacks Investment Research cut shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Finally, TheStreet upgraded shares of Wave Life Sciences from a “d+” rating to a “c-” rating in a research note on Friday, January 5th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Wave Life Sciences presently has a consensus rating of “Buy” and an average price target of $53.40.
Shares of WVE stock opened at $39.80 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.67 and a current ratio of 7.67. Wave Life Sciences has a 52 week low of $15.15 and a 52 week high of $55.95.
Wave Life Sciences (NASDAQ:WVE) last announced its earnings results on Monday, March 12th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The company had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.63 million. Wave Life Sciences had a negative return on equity of 66.73% and a negative net margin of 2,754.73%.
Large investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its position in shares of Wave Life Sciences by 6.2% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 56,537 shares of the company’s stock valued at $1,230,000 after buying an additional 3,325 shares in the last quarter. California State Teachers Retirement System raised its position in shares of Wave Life Sciences by 43.8% in the 2nd quarter. California State Teachers Retirement System now owns 21,009 shares of the company’s stock valued at $391,000 after buying an additional 6,400 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in Wave Life Sciences during the 3rd quarter worth approximately $2,634,000. Point72 Asset Management L.P. acquired a new position in Wave Life Sciences during the 3rd quarter worth approximately $13,679,000. Finally, Artal Group S.A. acquired a new position in Wave Life Sciences during the 4th quarter worth approximately $3,232,000. Institutional investors own 79.40% of the company’s stock.
In other news, insider Michael A. Panzara sold 511 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $52.10, for a total value of $26,623.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Chris Francis sold 21,639 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $55.40, for a total transaction of $1,198,800.60. The disclosure for this sale can be found here. Insiders sold a total of 24,466 shares of company stock valued at $1,321,808 in the last quarter. Corporate insiders own 53.00% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Wave Life Sciences Ltd to Post Q1 2019 Earnings of ($0.62) Per Share, Leerink Swann Forecasts (NASDAQ:WVE)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/leerink-swann-comments-on-wave-life-sciences-ltds-q1-2019-earnings-wve.html.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Get a free copy of the Zacks research report on Wave Life Sciences (WVE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.